NRXS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
NRXS 近期報酬表現
-1.62%
Neuraxis inc
4.57%
同產業平均
0.12%
S&P500
與 NRXS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NNOX | Nano-x imaging ltd | 4 分 | 5 分 | 4 分 | 1 分 | 1 分 | |
AORT | Artivion inc | 3 分 | 4 分 | 2 分 | 2 分 | 1 分 | |
ELMD | Electromed, incorporation | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
EKSO | Ekso bionics holdings inc | 4 分 | 3 分 | 4 分 | 1 分 | 1 分 | |
BWAY | Brainsway ltd | 3 分 | 3 分 | 2 分 | 1 分 | 1 分 |
- NNOX Nano-x imaging ltd價值 4 分趨勢 5 分波段 4 分籌碼 1 分股利 1 分查看更多
NRXS 公司資訊
Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. Other indications in its pipeline are comprised of functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.